Mylan Laboratories plans to buy King Pharmaceuticals in a $4 billion deal that could make the generic maker a larger player in the brand-name market, according to sources. The Mylan acquisition would follow a recent trend of generics entering the innovative drug market by acquiring other companies, while the size of the Mylan buy could help create a new wave of such activity.

Related Summaries